{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:03:22Z","timestamp":1777874602239,"version":"3.51.4"},"posted":{"date-parts":[[2026,4,30]]},"group-title":"In Review","reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,4,9]]},"abstract":"<title>Abstract<\/title>\n                <p>Achromobacter infections pose significant challenges to people with Cystic Fibrosis (CF). This microbe often becomes multidrug resistant (MDR) or extensively drug resistant (XDR), leaving physicians with few antibiotic treatment options. It is a growing problem in people with CF because it is difficult to eliminate with antibiotics, leading to chronic lung infections that increasingly acquire antibiotic resistance. We have been searching for alternative therapies for Achromobacter infection and identified a cadre of 26 bacteriophages (viruses that attack bacteria) that target it that could allow us to reduce reliance on antibiotics. We tested these phages against a collection of 56 MDR and XDR clinical Achromobacter isolates and found that all were susceptible to multiple of these phages. We also evaluated whether we could restore the activity of certain antibiotics by using them as adjunctive therapy to phage treatment in vitro. We found that when meropenem (a beta lactam antibiotic) was added to phage treatment, susceptibility to meropenem was demonstrated in many isolates regardless of whether the Achromobacter was initially susceptible to meropenem. The data presented here suggests that combination therapy using meropenem with an active phage should be considered for treatment of Achromobacter infections regardless of pre-existing antibiotic susceptibility.<\/p>","DOI":"10.21203\/rs.3.rs-9371970\/v1","type":"posted-content","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:03:56Z","timestamp":1777579436000},"source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic resistant Achromobacter xylosoxidans are highly susceptible to bacteriophages and often are killed synergistically by phage\/antibiotic combinations"],"prefix":"10.21203","author":[{"given":"David","family":"Pride","sequence":"first","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manola","family":"Orlatti","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norhan","family":"Turki","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Tourneur","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoolwanti","family":"Rani","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Leonard","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Kanhirun","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Blanc","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Su","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixian","family":"Huang","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Koch","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Pride","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Oh","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bates","sequence":"additional","affiliation":[{"name":"University of California San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Amamoto","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Carrico","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethzabe Serrano","family":"Buelna","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Knight","sequence":"additional","affiliation":[{"name":"UC San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bradley","sequence":"additional","affiliation":[{"name":"UCSD, Rady Childrens Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Conrad","sequence":"additional","affiliation":[{"name":"UCSD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Ana Cobi\u00e1n G\u00fcemes1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1403168","DOI":"10.3389\/fmicb.2024.1403168","article-title":"Emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability","volume":"15","author":"Sharma S","year":"2024","unstructured":"Sharma, S., Chauhan, A., Ranjan, A., et al.: Emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability. Front. Microbiol. 15, 1403168 (2024)","journal-title":"Front. Microbiol."},{"issue":"3","key":"ref2","article-title":"Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options","volume":"14","author":"Geremia N","year":"2025","unstructured":"Geremia, N., Marino, A., De Vito, A., et al.: Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options. Antibiot. (Basel) ; 14(3). (2025)","journal-title":"Antibiot. (Basel)"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","article-title":"Molecular mechanisms of antibiotic resistance revisited","volume":"21","author":"Darby EM","year":"2023","unstructured":"Darby, E.M., Trampari, E., Siasat, P., et al.: Molecular mechanisms of antibiotic resistance revisited. Nat. Rev. Microbiol. 21(5), 280\u2013295 (2023)","journal-title":"Nat. Rev. Microbiol."},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01025-20","article-title":"Achromobacter Infections and Treatment Options","volume":"64","author":"Isler B","year":"2020","unstructured":"Isler, B., Kidd, T.J., Stewart, A.G., Harris, P., Paterson, D.L.: Achromobacter Infections and Treatment Options. Antimicrob. Agents Chemother. ; 64(11). (2020)","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"e1013067","DOI":"10.1371\/journal.ppat.1013067","article-title":"Achromobacter spp.: Emerging pathogens in the cystic fibrosis lung","volume":"21","author":"Bhowmik N","year":"2025","unstructured":"Bhowmik, N., Stubbendieck, R.M.: Achromobacter spp.: Emerging pathogens in the cystic fibrosis lung. PLoS Pathog. 21(4), e1013067 (2025)","journal-title":"PLoS Pathog"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jcf.2022.11.001","article-title":"Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis","volume":"22","author":"Kerem E","year":"2023","unstructured":"Kerem, E., Orenti, A., Zolin, A., Annicchiarico, L., Drevinek, P., authors Ewtloc: Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis. J. Cyst. Fibros. 22(2), 334\u2013343 (2023)","journal-title":"J. Cyst. Fibros."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e0087025","DOI":"10.1128\/msphere.00870-25","article-title":"Achromobacter xylosoxidans isolates exhibit genome diversity, variable virulence, high levels of antibiotic resistance, and potential intrahost evolution","author":"Acharya P","year":"2026","unstructured":"Acharya, P., Lloyd, C., Lam, N.T., et al.: Achromobacter xylosoxidans isolates exhibit genome diversity, variable virulence, high levels of antibiotic resistance, and potential intrahost evolution. mSphere : e0087025. (2026)","journal-title":"mSphere"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2026.e44516","article-title":"High diversity of Achromobacter sp. isolation from children with CF, a retrospective case-control study","volume":"12","author":"Antoun N","year":"2026","unstructured":"Antoun, N., Marchandin, H., Houdouin, V., Mayer Lacrosniere, S.: High diversity of Achromobacter sp. isolation from children with CF, a retrospective case-control study. Heliyon ; 12(2). (2026)","journal-title":"Heliyon"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"127140","DOI":"10.1016\/j.micres.2022.127140","article-title":"Achromobacter spp. prevalence and adaptation in cystic fibrosis lung infection","volume":"263","author":"Veschetti L","year":"2022","unstructured":"Veschetti, L., Boaretti, M., Saitta, G.M., et al.: Achromobacter spp. prevalence and adaptation in cystic fibrosis lung infection. Microbiol. Res. 263, 127140 (2022)","journal-title":"Microbiol. Res."},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","DOI":"10.3390\/v15081665","article-title":"Compounding Achromobacter Phages for Therapeutic Applications","volume":"15","author":"Cobian Guemes AG","year":"2023","unstructured":"Cobian Guemes, A.G., Le, T., Rojas, M.I., et al.: Compounding Achromobacter Phages for Therapeutic Applications. Viruses ; 15(8). (2023)","journal-title":"Viruses"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"e0072425","DOI":"10.1128\/jcm.00724-25","article-title":"Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience","volume":"63","author":"Bayless DR","year":"2025","unstructured":"Bayless, D.R., Dumais, M.G., McHugh, J.W., et al.: Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience. J. Clin. Microbiol. 63(10), e0072425 (2025)","journal-title":"J. Clin. Microbiol."},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/INF.0000000000004000","article-title":"Bacteriophage Therapy of Multidrug-resistant Achromobacter in an 11-Year-old Boy With Cystic Fibrosis Assessed by Metagenome Analysis","volume":"42","author":"Bradley JS","year":"2023","unstructured":"Bradley, J.S., Hajama, H., Akong, K., et al.: Bacteriophage Therapy of Multidrug-resistant Achromobacter in an 11-Year-old Boy With Cystic Fibrosis Assessed by Metagenome Analysis. Pediatr. Infect. Dis. J. 42(9), 754\u2013759 (2023)","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mib.2019.03.005","article-title":"Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy","volume":"51","author":"Segall AM","year":"2019","unstructured":"Segall, A.M., Roach, D.R., Strathdee, S.A.: Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy. Curr. Opin. Microbiol. 51, 46\u201350 (2019)","journal-title":"Curr. Opin. Microbiol."},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1038\/s41467-025-64218-z","article-title":"CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial","volume":"16","author":"Knoll RL","year":"2025","unstructured":"Knoll, R.L., Brauny, M.M., Robert, E., et al.: CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. Nat. Commun. 16(1), 10111 (2025)","journal-title":"Nat. Commun."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fcimb.2017.00224","article-title":"Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin","volume":"7","author":"Filipic B","year":"2017","unstructured":"Filipic, B., Malesevic, M., Vasiljevic, Z., et al.: Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin. Front. Cell. Infect. Microbiol. 7, 224 (2017)","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"954","key":"ref16","first-page":"413","article-title":"Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter","volume":"22","author":"Winzig FGS","year":"2022","unstructured":"Winzig, F.G.S., Lee, A., W\u00fcrstle, S., Stanley, G.L., Capuano, I., Neuringer, I., Koff, J.L., Turner, P.E., Chan, B.K.: Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter. Yale J. Biol. Med. Dec 22(954), 413\u2013427 (2022)","journal-title":"Yale J. Biol. Med."},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","DOI":"10.3390\/v13010060","article-title":"A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient","volume":"13","author":"Lebeaux D","year":"2021","unstructured":"Lebeaux, D., Merabishvili, M., Caudron, E., et al.: A Case of Phage Therapy against Pandrug-Resistant Achromobacter xylosoxidans in a 12-Year-Old Lung-Transplanted Cystic Fibrosis Patient. Viruses ; 13(1). (2021)","journal-title":"Viruses"},{"key":"ref18","author":"Khong E","year":"2023","unstructured":"Khong, E., Oh, J., Jimenez, J.M., et al.: A simple solid media assay for detection of synergy between bacteriophages and antibiotics. bioRxiv (2023)"},{"key":"ref19","author":"Ghatbale P","year":"2024","unstructured":"Ghatbale, P., Sah, G.P., Dunham, S., et al.: In-vitro resensitization of multidrug resistant clinical isolates of Enterococcus faecium and faecalis through phage-antibiotic synergy. bioRxiv (2024)"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","DOI":"10.3390\/v14071542","article-title":"An Optimized Checkerboard Method for Phage-Antibiotic Synergy Detection","volume":"14","author":"Nikolic I","year":"2022","unstructured":"Nikolic, I., Vukovic, D., Gavric, D., et al.: An Optimized Checkerboard Method for Phage-Antibiotic Synergy Detection. Viruses ; 14(7). (2022)","journal-title":"Viruses"},{"issue":"9","key":"ref21","article-title":"Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility","volume":"11","author":"Kunz Coyne AJ","year":"2022","unstructured":"Kunz Coyne, A.J., Stamper, K., Kebriaei, R., et al.: Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility. Antibiot. (Basel) ; 11(9). (2022)","journal-title":"Antibiot. (Basel)"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s44259-026-00186-8","article-title":"Phage-meropenem synergy against OXA-48-producing Klebsiella pneumoniae clinical isolates","volume":"4","author":"Cantallops I","year":"2026","unstructured":"Cantallops, I., Ferriol-Gonzalez, C., Barcos-Rodriguez, T., et al.: Phage-meropenem synergy against OXA-48-producing Klebsiella pneumoniae clinical isolates. NPJ Antimicrob. Resist. Dec 4(1), 12 (2026)","journal-title":"NPJ Antimicrob. Resist."},{"key":"ref23","article-title":"Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii","author":"Luo J","year":"2024","unstructured":"Luo, J., Liu, M., Ai, W., et al.: Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. (2024)","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2023.10.029","article-title":"Alginate microbeads and hydrogels delivering meropenem and bacteriophages to treat Pseudomonas aeruginosa fracture-related infections","volume":"364","author":"Chen B","year":"2023","unstructured":"Chen, B., Benavente, L.P., Chitto, M., et al.: Alginate microbeads and hydrogels delivering meropenem and bacteriophages to treat Pseudomonas aeruginosa fracture-related infections. J. Control Release. Dec 364, 159\u2013173 (2023)","journal-title":"J. Control Release"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14787210.2021.1945922","article-title":"Proposed amendments regarding the definitions of multidrug-resistant and extensively drug-resistant bacteria","volume":"20","author":"Rafailidis PI","year":"2022","unstructured":"Rafailidis, P.I., Kofteridis, D.: Proposed amendments regarding the definitions of multidrug-resistant and extensively drug-resistant bacteria. Expert Rev. Anti Infect. Ther. Dec 20(2), 139\u2013146 (2022)","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"D1","key":"ref26","doi-asserted-by":"crossref","first-page":"D678","DOI":"10.1093\/nar\/gkac1003","article-title":"Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR","volume":"51","author":"Olson RD","year":"2023","unstructured":"Olson, R.D., Assaf, R., Brettin, T., et al.: Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR. Nucleic Acids Res. Dec 51(D1), D678\u2013D89 (2023)","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"e11147","DOI":"10.1371\/journal.pone.0011147","article-title":"progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement","volume":"5","author":"Darling AE","year":"2010","unstructured":"Darling, A.E., Mau, B., Perna, N.T.: progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS One. Dec 5(6), e11147 (2010)","journal-title":"PLoS One"},{"issue":"22","key":"ref28","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1093\/bioinformatics\/btz265","article-title":"PHANOTATE: a novel approach to gene identification in phage genomes","volume":"35","author":"McNair K","year":"2019","unstructured":"McNair, K., Zhou, C., Dinsdale, E.A., Souza, B., Edwards, R.A.: PHANOTATE: a novel approach to gene identification in phage genomes. Bioinformatics. Dec 35(22), 4537\u20134542 (2019)","journal-title":"Bioinformatics"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10482-017-0844-4","article-title":"A large-scale evaluation of algorithms to calculate average nucleotide identity","volume":"110","author":"Yoon SH","year":"2017","unstructured":"Yoon, S.H., Ha, S.M., Lim, J., Kwon, S., Chun, J.: A large-scale evaluation of algorithms to calculate average nucleotide identity. Antonie Van Leeuwenhoek. Dec 110(10), 1281\u20131286 (2017)","journal-title":"Antonie Van Leeuwenhoek"},{"issue":"15","key":"ref30","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/bioinformatics\/btx157","article-title":"ViPTree: the viral proteomic tree server","volume":"33","author":"Nishimura Y","year":"2017","unstructured":"Nishimura, Y., Yoshida, T., Kuronishi, M., Uehara, H., Ogata, H., Goto, S.: ViPTree: the viral proteomic tree server. Bioinformatics. Dec 33(15), 2379\u20132380 (2017)","journal-title":"Bioinformatics"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9371970\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9371970\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:04:00Z","timestamp":1777579440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9371970\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9371970\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,4,30]]},"subtype":"preprint"}}